- Home
- AWK vs ILMN Comparison
AWK vs ILMN Comparison
Compare AWK & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWK
- ILMN
- Stock Information
- Founded
- AWK 1886
- ILMN 1998
- Country
- AWK United States
- ILMN United States
- Employees
- AWK N/A
- ILMN N/A
- Industry
- AWK Water Supply
- ILMN Medical Specialities
- Sector
- AWK Utilities
- ILMN Health Care
- Exchange
- AWK Nasdaq
- ILMN Nasdaq
- Market Cap
- AWK 28.5B
- ILMN 22.9B
- IPO Year
- AWK 2008
- ILMN 2000
- Fundamental
- Price
- AWK $132.38
- ILMN $141.09
- Analyst Decision
- AWK Hold
- ILMN Buy
- Analyst Count
- AWK 8
- ILMN 20
- Target Price
- AWK $141.88
- ILMN $160.68
- AVG Volume (30 Days)
- AWK 1.3M
- ILMN 2.1M
- Earning Date
- AWK 10-30-2024
- ILMN 11-04-2024
- Dividend Yield
- AWK 2.31%
- ILMN N/A
- EPS Growth
- AWK 3.70
- ILMN N/A
- EPS
- AWK 5.03
- ILMN N/A
- Revenue
- AWK $4,515,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- AWK $8.31
- ILMN N/A
- Revenue Next Year
- AWK $6.19
- ILMN $4.28
- P/E Ratio
- AWK $26.29
- ILMN N/A
- Revenue Growth
- AWK 9.24
- ILMN N/A
- 52 Week Low
- AWK $113.34
- ILMN $97.36
- 52 Week High
- AWK $150.68
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- AWK 40.05
- ILMN 48.42
- Support Level
- AWK $130.18
- ILMN $138.88
- Resistance Level
- AWK $139.49
- ILMN $144.00
- Average True Range (ATR)
- AWK 2.48
- ILMN 4.58
- MACD
- AWK -0.36
- ILMN -0.05
- Stochastic Oscillator
- AWK 23.09
- ILMN 69.62
About AWK American Water Works Company Inc.
American Water Works is the largest investor-owned us water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.